Friday, February 27, 2026

Warren Buffett hands over his pen

A new CEO will write Berkshire letter
View in browser
Bloomberg

Berkshire Hathaway hits a milestone this weekend as it releases its first annual letter written by someone other than Warren Buffett. Alexandre Rajbhandari, who covers the company for Bloomberg News, writes about what to look for. Plus: Why gold above $5,000 an ounce looks like the new normal, and Europe's biotech companies are enlisting minipigs for drug testing. And there's a new episode of the Everybody's Business podcast.

If this newsletter was forwarded to you, click here to sign up.

Warren Buffett enthusiasts are about to get a taste of what life at Berkshire Hathaway Inc. looks like without its legendary chief executive officer. On Saturday, his conglomerate will publish its traditional annual letter. But for the first time in more than six decades, the missive won't be written by Buffett himself. His successor, Greg Abel, will be the author instead.

For Buffett fans, this is the end of an era. The billionaire's pearls of wisdom, aphorisms and life advice have turned the trove of letters into a must-read archive. Far from the reserved addresses of most of his peers, the billionaire's musings have provided innumerable clues into his perception of the world, helping build his legacy of a successful and sophisticated investor—as well as a highly relatable person.

Now Abel needs to find his own voice.

Abel in 2020. Photographer: Andrew Harrer/Bloomberg

"Is Greg Abel going to carry on that mantle of a folksy legend? Or is he going to basically just put out a very professional, to-the-point, buttoned-up shareholder letter?" asks Cathy Seifert, a CFRA Research analyst.

Whichever tone Abel eventually chooses, shareholders of the conglomerate will be looking for clues on how the new CEO intends to run things at Berkshire—starting with how he'll communicate with them going forward. Berkshire, the only public company of its size without a dedicated investor relations function, is notorious for its relative lack of transparency. 

"Quite frankly, I think if given a choice, investors would rather have transparency over folklore," Seifert says.

Berkshire could maybe start with a clear communication on the firm's shareholder return policy. While Buffett always ruled out a dividend—except once, an event he recently recalled as a "bad dream"—Berkshire has in the past repurchased some of its own shares when the billionaire thought they were trading below their intrinsic value.

The subjective criteria means investors were often left in the dark. After more than a year without buybacks despite a whopping $381.7 billion cash pile and shares still below last May's all-time peak, analysts say it could be a good time for Abel to come up with more quantifiable guidance.

For instance, "there might just be more of a target that, absent investment opportunities, we should expect some proportion of free cash flow to be invested in buybacks going forward," says James Shanahan, an analyst for Edward Jones. "Otherwise he's subjecting himself to criticism in the annual meeting."

The letter could also be the occasion for Abel to clarify his priorities in his new role, in particular his ambition for the firm's closely watched $274 billion stock portfolio. 

After Buffett's retirement and the departure of Todd Combs for JPMorgan Chase & Co., the firm is left with only one of its historical stock pickers, Ted Weschler. Abel now has to oversee a sprawling empire spanning multiple industries and employing almost 400,000 people, and may not have the bandwidth to dedicate much time to investing—an area where he lacks a documented track record. 

"If he had to make a difficult choice, I think he would choose to de-emphasize the importance of making individual equity investments and focus more on the operations of the underlying portfolio companies—and potentially acquisitions in those areas," Shanahan says.

Away from the letter, investors will also get access to Berkshire Hathaway's fourth-quarter results, the last under Buffett's leadership. Outsiders often scrutinize the firm's earnings for clues about the health of the broader economy. A number of uncertainties—from President Donald Trump's trade policy to geopolitical risks—might translate into softer earnings at the conglomerate.

"Overall, I'm looking for sort of a moderation in results," Seifert says. "The consumer-facing businesses are certainly likely to have some headwinds."

In Brief

  • Netflix dropped out of the fight to buy Warner Bros. Discovery, clearing the way for Paramount Skydance to clinch its deal for the historic Hollywood studio.
  • Anthropic rejected the Pentagon's latest offer in a dispute over safeguards around the use of its artificial intelligence technology by the US military.
  • A trove of Deutsche Bank files has been released as part of the US government's Jeffrey Epstein investigation, shedding light on family offices for some of the world's wealthiest people.

Get the Bloomberg Businessweek print magazine delivered to you and unlimited access to Businessweek stories on Businessweek.com. Annual subscription for $99.

On the Podcast

It's a rapturous time to be in prediction markets, but is the promise of Kalshi and Polymarket to "financialize everything" a net good for society, or is it gambling in sheep's clothing? Centuries of history point toward a potential answer. From the On Air Fest in New York City, the Everybody's Business podcast from Bloomberg Businessweek and Pushkin Industries' Business History come together to explain the lengths people will go to for a life-changing payday.

Listen and subscribe on Apple, Spotify, iHeart and the Bloomberg Terminal.

Great Fortunes

$1.3 billion
That's how much John D. Rockefeller was worth in 1915, or $40 billion in today's dollars, according to a Bloomberg News analysis of historical data. As Elon Musk approaches trillionaire status, Ben Steverman writes about what we can learn from the US's first billionaire.

Who's Buying Gold Now?

Photo illustration: Derek Brahney for Bloomberg Businessweek

Obioha Okereke used to think investing in gold was for risk-averse retirees. "I felt it was boring, to put it bluntly," says the technology consultant, 29, who's been meticulously managing his ambitious, growth-focused portfolio since his senior year of high school. But as his tech-heavy investments started to wobble last year and the metal extended its climb, Okereke decided to give gold a go.

He bought into his first gold exchange-traded fund in September, first with $100, adding over $2,000 more since. It's a small share of his overall holdings, but one he intends to keep increasing: His gold investment is up nearly 17% since he started, outperforming the rest of his portfolio. "I wanted something that was going to be a hedge against the uncertainty and the random swings," Okereke says. "Gold just seemed to make sense."

Yvonne Yue Li and Ella Feldman write he's part of a new crop of global traders: The Buyers Behind Gold's $5,000 Breakthrough

Minipigs for Medical Research 

Ellegaard Gottingen minipigs in the lab. Source: Ellegaard Gottingen Minipigs

Jens Ellegaard's pig farm is not like others nestled among the rapeseed and wheat fields of eastern Denmark. There's no livestock smell, muddy yards or clattering machinery. Breeding units are divided into tightly managed zones where staff follow strict hygiene protocols, water is treated with ultraviolet light, and temperature is regulated by a geothermal system that circulates air through 30 kilometers (19 miles) of underground piping.

The site, Ellegaard Gottingen Minipigs A/S, is more of a biosecurity facility. Its pigs are smaller than standard farm pigs, with some varieties genetically modified to mimic human immune responses and organ function. The animals contributed to the development of Novo Nordisk A/S's blockbuster diabetes and obesity treatments, Ozempic and Wegovy. And they're being used by other major pharmaceutical companies to find therapies for illnesses like whooping cough, diseases such as Huntington's and Parkinson's, and certain types of cancer.

Sara Sjolin says the animals are emerging as a key part of the European Union's drive to create a more resilient testing regime: The $3,000 Minipig Powering Europe's Drug Pipeline

Related: Novo Nordisk's Torrid Week Erases Last of Wegovy-Fueled Gains

Security for Sale

"What motivated us was patriotism. We don't want to sell a single acre to Russians, land our fathers and grandfathers defended in the war and the Russians failed to seize."
Hannu Luotola
A retired brigadier general
For decades, Finland allowed investors from Russia to buy real estate, and they quietly amassed thousands of properties on NATO's eastern flank, some close to military bases and critical infrastructure. Now, the Finnish government is grappling with how to tell what's innocent investment and what's a threat. Read The Big Take.

Play Alphadots!

Our daily word puzzle with a plot twist.

alphadots

Today's clue is: Paddle battle?

Play now!

More From Bloomberg

Like Businessweek Daily? Check out these newsletters:

  • Odd Lots, with Joe Weisenthal and Tracy Alloway, explores the most interesting topics in finance, markets and economics.
  • Power On, with Mark Gurman, has the inside scoop on all things Apple and consumer tech.
  • Washington Edition follows Trump's second term through the lens of business, markets and the economy.
  • Bloomberg Weekend discusses big ideas and open questions in the fascinating places where finance, life and culture meet.
  • Business of Food covers how the world feeds itself in a changing economy and climate, from farming to supply chains to consumer trends.

Explore all Bloomberg newsletters.

Follow Us

Like getting this newsletter? Subscribe to Bloomberg.com for unlimited access to trusted, data-driven journalism and subscriber-only insights.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Businessweek Daily newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices

No comments:

Post a Comment

This Data Shows Where the AI Trade Is Going

Nothing that can be done on a computer is safe... This Data Shows Where the AI Trade Is Going VIEW IN BROWSE...